AMRI names quality control director for troubled plant, following lead of J&J, Novartis, others

Another pharmaceutical manufacturer has announced that it is beefing up quality control management after running afoul of FDA inspectors. AMRI ($AMRI) has named Tom McGrath as director of quality for aseptic services at its Burlington, MA, facility, which last year was cited in an FDA warning letter. A string of companies including Johnson & Johnson ($JNJ), Novartis ($NVS) and Hospira ($HSP) have recently named new leaders ranging from the plant level to the executive suite, whose focus, at least in part, will be on improving GMP in plants. Release | Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.